

1 **Supplementary Table 3. Adjusted overall survival for elderly women (age \geq 70 years old)**
 2 **with ductal carcinoma *in situ*, ER+ tumors, including tumor size as a variable ($n = 9,249$,**
 3 **Events = 1,790)**

	Hazard ratio (95%CI)	P-value	Overall P-value
Treatment Group			< 0.001
Lumpectomy alone (no Radiation or Endocrine Therapy)	REF	-	
Lumpectomy + Endocrine Therapy (no Radiation)	0.746 (0.621-0.895)	0.002	
Lumpectomy + Radiation or Mastectomy (no Endocrine Therapy)	0.804 (0.723-0.895)	< 0.001	
(Lumpectomy + Radiation or Mastectomy) + Endocrine therapy	0.62 (0.54-0.712)	< 0.001	
Age (years)	1.093 (1.083-1.103)	< 0.001	< 0.001
Year of diagnosis	0.974 (0.954-0.995)	0.02	0.02
Race/Ethnicity			0.008
Non-Hispanic White	REF	-	
Non-Hispanic Black	0.913 (0.775-1.075)	0.28	
Hispanic	0.61 (0.442-0.842)	0.003	
Other	0.812 (0.588-1.12)	0.20	
Charlson/Deyo comorbidity score			< 0.001
0	REF	-	
1	1.47 (1.299-1.665)	< 0.001	
≥ 2	2.378 (1.963-2.882)	< 0.001	
Tumor size (cm)	0.999 (0.996-1.003)	0.74	0.74
PR status			0.007

	Hazard ratio (95%CI)	P-value	Overall P-value
PR+	REF	-	
PR-	1.176 (1.045-1.323)	0.007	

4 Hazard ratio reported for risk of death. Model also adjusted for income, education, insurance,
5 facility type and location. ER: estrogen receptor; PR: progesterone receptor

6